Pac Premier
Giving Guide
You are here:  Home  >  Central Coast Health Watch  >  Current Article

Amgen’s Blincyto gets approval in Japan

By   /   Monday, September 24th, 2018  /   Comments Off on Amgen’s Blincyto gets approval in Japan

    Print       Email
Thousand Oaks biotech giant Amgen announced Sept. 24 that its leukemia treatment Blincyto had received approval from Japanese regulators. The drug is the first approval for the Japanese joint venture Amgen Astellas BioPharma and uses the company’s bi-specific T cell engager, or BiTE platform, which helps the body’s immune system target cancer cells. Blincyto has…


    This article is only available to Business Times subscribers
  • Subscribers: LOG IN or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.
    Print       Email